U.S. Markets closed

Brooklyn ImmunoTherapeutics, Inc. (BTX)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
15.58+0.67 (+4.49%)
At close: 4:00PM EDT
15.90 +0.32 (2.05%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close14.91
Open14.74
Bid16.13 x 1100
Ask16.22 x 1000
Day's Range14.50 - 16.43
52 Week Range2.26 - 80.67
Volume4,172,530
Avg. Volume7,499,415
Market Cap646.791M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Brooklyn ImmunoTherapeutics Executes Letter of Intent to Acquire Novellus Therapeutics
    GlobeNewswire

    Brooklyn ImmunoTherapeutics Executes Letter of Intent to Acquire Novellus Therapeutics

    Novellus Therapeutics develops next-generation mesenchymal stem cell products using licensed patented mRNA cell reprogramming and gene editing technologiesNEW YORK, June 14, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics LLC (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced it has executed a non-binding le

  • Brooklyn ImmunoTherapeutics Set to Join Russell 3000 Index
    GlobeNewswire

    Brooklyn ImmunoTherapeutics Set to Join Russell 3000 Index

    BROOKLYN, N.Y., June 09, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic disorders, today announced Brooklyn’s addition to the Russell 3000 Index. This milestone will take place at the conclusion of the 2021 Russell Indexes’ annual reconstitution, effective after the U.S. marke

  • Brooklyn ImmunoTherapeutics Welcomes Dr. Kevin A. D’Amour as Chief Scientific Officer
    GlobeNewswire

    Brooklyn ImmunoTherapeutics Welcomes Dr. Kevin A. D’Amour as Chief Scientific Officer

    BROOKLYN, N.Y., June 08, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic disorders, today announced the appointment of Kevin A. D’Amour, Ph.D. as its Chief Scientific Officer. Dr. D’Amour joins Brooklyn from ViaCyte, Inc., a private, clinical stage company developing stem cell-